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Abstract 
Background 
We have investigated the role that the mutation rate and the structure of 
genetic variation at a locus play in determining whether a gene is involved in 
disease. We predict that the mutation rate and its genetic diversity should be 
higher in genes associated with disease, unless all genes that could cause 
disease have already been identified.  
Results 
Consistent with our predictions we find that genes associated with Mendelian 
and complex disease are substantially longer than non-disease genes. 
However, we find that both Mendelian and complex disease genes are found 
in regions of the genome with relatively low mutation rates, as inferred from 
intron divergence between humans and chimpanzees. Complex disease gene 
are predicted to have higher rates of non-synonymous mutation than non-
disease genes, but the opposite pattern is found in Mendelian disease genes. 
Finally, we find that disease genes are in regions of significantly elevated  
genetic diversity, even when variation in the rate of mutation is controlled for. 
The effect is small nevertheless. 
Conclusions 
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Our results suggest that variation in the genic mutation rate and the genetic 
architecture of the locus play a minor role in determining whether a gene is 
associated with disease. 
 
 
Introduction 
Why do humans suffer from the diseases that we do? In part this is clearly 
due to our anatomy and physiology, and that of the organisms that infect us - 
we cannot have a disease of an organ that we do not possess. But why do we 
suffer from cystic fibrosis rather than some other disease of the lungs? One 
simple reason might be variation in the mutation rate. Those genes and 
genomic regions that have high mutation rates are more likely to generate 
disease mutations, and hence be associated with a disease. The rate of 
mutation of a locus will depend upon two factors: the rate of mutation per site 
and the number of sites at which a mutation can generate a disease 
phenotype. The per site mutation rate is known to vary across the human 
genome at a number of different scales such that some genes have mutation 
rates that are several fold higher than other genes (reviewed in [1]). Genes 
also vary considerably in their length, with some of the largest, such as the 
dystrophin gene, being association with disease.  
 
A more subtle factor affecting the likelihood of a gene being associated with a 
disease is the genealogy. At each site in the genome there is an underlying 
genealogy whereby every chromosome in the population is related via a 
bifurcating tree to every other chromosome at that site. If there is no 
recombination between sites then sites share the same genealogy. The shape 
and depth of the genealogy depends on several factors. The first is chance; 
for example, the average total length of a genealogy for a neutral locus in a 
population of stationary size is expected to be proportional to 4N generations 
in a diploid species, where N is the population size, but this is expected to 
have a variance of at least (4N)2 generations [2]. Second, the genealogy 
depends on the effective population size of the locus (Ne). Ne is thought to 
vary across the human genome as a consequence of natural selection [3,4]. 
Selection can reduce the Ne of a genomic region through either a selective 
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sweep caused by the passage of an advantageous mutation through the 
population [5], or via background selection caused by the removal of 
deleterious mutations [6]. Those regions of the genome with low rates of 
recombination or a high density of selected sites are expected to have low Ne, 
and this is expected to reduce the genetic diversity of neutral and weakly 
selected variants in these regions (reviewed in [7]). Analyses suggest that Ne 
varies across the human genome by a few-fold [4]. The effective population 
size is not expected to affect the frequency of deleterious mutations in which 
the product of Ne and the strength selection is greater than one. However, 
stochastic factors are expected to be important irrespective of the selection 
acting upon a mutation. 
 
Previous analyses have shown that Mendelian disease genes are 30% longer 
than non-disease genes [8,9].  Comparative analyses have also shown that 
genes associated with Mendelian diseases have significantly, but only slightly 
higher rates of mutation per site, as inferred from levels of synonymous 
divergence between species [8,10]. The rather modest differences between 
disease and non-diseases genes in the inferred mutation rate might be due to 
time frame over which the mutation rate was inferred: Smith and Eyre-Walker 
[8] considered the divergence between human and mouse, and Huang et al. 
[10] considered the divergence between mouse and rat. This will give a poor 
estimate of the current mutation rate at a locus in humans because the 
relative mutation rate of a locus appears to have evolved through time [1,11]. 
The mutation rate has also recently been predicted, based on a model fitted to 
the locations of de novo mutations in humans, to be slightly higher in disease 
associated genes [12], but the accuracy of this model is unproven, and they 
consider the total mutation rate of the exon, rather than the rate at non-
synonymous sites. Here we consider the divergence between humans and 
their most closely related extant relative, chimpanzee, as our measure of the 
mutation rate. We also consider whether the density of single nucleotide 
polymorphism is greater in disease than non-disease genes.  
 
 
Results 
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We predict that unless all possible diseases with a genetic basis, and all the 
genes that can cause them, have already been discovered, then genes 
associated with diseases should have genic mutation rates than non-disease 
genes, where the genic mutation rate is determined by the product of gene 
length and the mutation rate per site. We also predict that disease genes 
should be in relatively diverse regions of the genome. To investigate these 
predictions we compiled data from 17577 autosomal genes with introns, of 
which 854 genes are known to cause a Mendelian disease. We also analysed 
1732 genes in which the strongest signal in a genomic region in a genome 
wide association study (GWAS) lay within the boundaries of the gene (i.e. all 
exons and introns between the start and stop codon). The presence of an 
association signal within the boundaries of the gene does not necessarily 
mean that the causative mutation is within the protein coding sequence or 
even within the boundaries of the gene, and many of these associations may 
be in regulatory sequences [13]. We subsequently excluded genes on the sex 
chromosomes since the Y-chromosome is known to have a higher and the X-
chromosome a lower mutation rate than the autosomes [14]. This yielded a 
dataset of 17062 genes including 820 associated with a Mendelian disease 
and 1726 with a GWAS signal. 
 
Gene length 
Consistent with the hypothesis that disease genes should have higher overall 
rates of mutation we find, as others have in the past for genes causing 
Mendelian disease [8,9], that genes associated with disease are significantly 
longer, in terms of coding sequence (CDS) length, than non-disease genes - 
disease genes are ~50% longer than non-disease genes (One-way ANOVA 
p<0.001)(Figure 1). This is greater than in previous studies [8,9], but this is 
likely to be due to the improvement in genome annotation. Strikingly, the 
difference is as great for the GWAS as Mendelian disease genes despite the 
fact that many of the GWAS signals are likely to be outside the protein coding 
sequence [13]. GWAS genes might have longer CDSs because intron and 
CDS lengths are correlated (r = 0.30, p<0.001), and long introns are more 
likely to contain a SNP that causes the disease or tags a causative mutation 
somewhere in the vicinity of the gene. However, if we control for the 
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correlation between intron and CDS length by regressing CDS length against 
intron length and taking the residuals, we find that GWAS genes have longer 
CDSs, than non-disease genes, even given their longer introns (t-test 
p<0.001; similar results are obtained if we regress log CDS length against log 
intron length (p<0.001)). 
 
Mutation rates 
However, contrary to our expectations, we find that disease genes are found 
in regions of the genome with significantly lower mutation rates, as measured 
by intron divergence between human and chimpanzee. The difference is 
highly significant (one-way ANOVA p <0.001), but the difference is small with 
disease genes having approximately 5% lower intron divergence than non-
disease genes (Figure 2a). The pattern differs between CpG and non-CpG 
sites, with disease genes having higher divergence at CpG sites and lower 
divergence at non-CpG sites (results not shown). However, if we calculate the 
expected non-synonymous mutation rate in the CDS by multiplying the 
proportion of non-synonymous sites that are CpG and non-CpG in the CDS by 
the respective levels of intron divergence, we find that complex disease genes 
have slightly higher predicted mutation rates than non-disease genes, but 
Mendelian disease genes have slightly lower mutation rates per site (p=0.041) 
(Figure 2b). As expected, both Mendelian and complex disease genes have 
significantly higher predicted rates of non-synonymous mutation (p<0.001), 
driven by the fact that disease genes have longer CDSs. 
 
 
The fact that Mendelian disease genes have lower predicted rates of non-
synonymous mutation per site is inconsistent with our hypothesis, but this 
might be due to the fact that they have features which predispose them to 
lower mutation rates - for example they might be transcribed at lower levels 
and hence have lower rates of mutation. Divergence at intronic and intergenic 
sites is known to be significantly correlated to a number of other variables 
including GC-content [3,15,16,17], recombination rate [3,16,18,19,20], 
replication time [15,21,22], distance to the telomere and centromere 
[3,15,16,23], gene density [3,16], nucleosome occupancy [11] and expression 
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level [24]. We confirm previous results and show that intron divergence is 
positive correlated to GC content, replication time (later genes have higher 
divergence) and male recombination rate, and negatively correlated to the 
distance to the telomere, distance to the centromere, female recombination 
rate, nucleosome occupancy and germ-line expression, within a multiple 
regression (Table 1). Similar patterns are evident for the predicted non-
synonymous mutation rate (Table 1). If we take the residuals from a multiple 
regression of intron divergence against all the genomic variables above we 
find that intron divergence does not differ significantly between disease and 
non-disease genes, but that the predicted rate of non-synonymous mutation is 
greater for both Mendelian and GWAS genes (ANOVA p<0.001), although 
this is only individually significant for GWAS genes (t-test p<0.001). 
 
Genetic diversity 
Although, disease genes are found in regions of the genome with relatively 
low rates of intron mutation we find that disease genes have a significantly 
greater density of polymorphisms segregating in their introns than non-
disease genes; the difference is 11% and 17% for the Mendelian and GWAS 
genes respectively (Figure 3a). If we divide the density of SNPs by the 
divergence of introns to calculate a quantity we might call the “realized” 
effective population size, we find that Mendelian and GWAS genes have 
significantly higher realized Ne values that are 9% and 12% greater than non-
disease genes (ANOVA p<0.001; t-test of Mendelian versus non-disease 
p<0.001; t-test of GWAS versus non-disease p<0.001). However, we find no 
evidence that the predicted non-synonymous population mutation rate in the 
CDS (calculated as the proportion of non-synonymous sites that are CpG 
multiplied by the SNP density at CpG sites in introns plus the proportion of 
non-synonymous sites that are non-CpG multiplied by the SNP density at 
non-CpG in introns) differs between disease and non-disease genes, but the 
calculation of the predicted non-synonymous population mutation rate is 
subject to considerable error because we have relatively few intron CpG sites 
and SNP density is very low in humans. 
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As with the predicted non-synonymous mutation rate, it is possible that 
disease genes have higher diversities and realized Ne values because 
disease genes have features that predispose them to higher values, not 
because by having higher values they are more likely to be associated with 
disease. We find that intron SNP density is positively correlated to GC content, 
female and male rates of recombination, the time of replication and distance 
to the centromere and negatively correlated to nucleosome occupancy, germ-
line expression and distance to the telomere (Table 1). If control for these 
factors by taking the residuals from the multiple regression we find that SNP 
density is still significantly greater in both Mendelian and GWAS genes, than 
in non-disease genes (ANOVA p<0.001; individual t-tests p<0.001). Likewise 
we find the realized Ne is positively correlated to all variables except GC 
content, nucleosome occupancy and male recombination rate (Table 1), and 
that after controlling for these associations, disease genes still have 
significantly greater realized Ne values than non disease genes (ANOVA 
p=0.019; individual t-tests Mendelian versus non-disease p=0.21, GWAS 
versus non-disease p=0.001). 
 
Although disease genes have a greater number of SNPs per bp than non-
disease genes the distribution of the genetic variation varies in an inconsistent 
manner between categories of genes; the average minor allele frequency is 
~10% greater in Mendelian, and ~10% lower in GWAS genes, than in non-
disease genes (ANOVA p <0.01)(Figure 3b).  
 
 
Discussion 
We have found that genes associated with disease are longer and reside in 
regions of the genome with greater intron diversities and realized effective 
population sizes than non-disease genes. This is consistent with a role for 
mutation and genetic variation in determining whether a gene becomes 
associated with disease. However, we do not find convincing evidence that 
the mutation rate per site is greater in disease genes than non-disease genes; 
only if we consider the predicted rate of non-synonymous mutation and 
control for various genomic variables do we find that both Mendelian and 
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complex disease genes have higher mutation rates than non-disease genes. 
Ad even then the differences seem small. Nevertheless, what is ultimately 
important is the mutation rate of the gene, and we find that the overall 
mutation rate of disease genes is greater than non-disease genes because 
disease genes are longer (p<0.001). The effect of gene length may be more 
conspicuous than for the other variables, because there is substantially more 
variation in CDS length per gene (coefficient of variation (CV) = 0.78) than in 
intron divergence (CV = 0.56), intron SNP density (CV = 0.42) and realized Ne 
(CV = 0.47); in reality the differences in CV are even larger because intron 
divergence, and in particular SNP density and realized Ne, are likely to be 
subject to large sampling error variances that CDS length is not. 
 
We have interpreted the fact that disease genes are longer than non-disease 
genes as evidence that genes with higher mutation rates are more likely to 
generate disease mutations, however, it is possible that disease genes are 
longer simply because genes involved in particular processes that could 
cause disease are longer. It is difficult to test this hypothesis without knowing 
all the genes that might cause disease. We have also interpreted the greater 
diversity in disease genes as being what causes them to be associated with 
disease. However, in the case of the complex disease genes this might simply 
reflect a bias towards a better ability to detect GWAS signals in regions of 
higher diversity. 
 
Interestingly, two observations in our analysis suggest that a reasonable 
proportion of the causative mutations being tagged by GWAS associations 
may be in protein coding sequences rather than in regulatory regions. First, 
we find that GWAS genes have longer CDSs than non-disease genes, even if 
we control for the fact that genes with longer CDSs have longer total intron 
length. Second, we find that GWAS genes have lower intron divergence than 
non-disease genes, but higher predicted non-synonymous mutation rates. 
 
Although, we have found that disease genes are longer than non-disease 
genes, and that they have greater diversity, realized effective population size, 
the differences are fairly small. It is therefore evident that either most disease 
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associated genes have been discovered, which seems unlikely, or that the 
function of the gene is far more important in determining whether a gene 
causes disease than its effective mutation rate. 
 
 
 
Materials and methods 
Genic mutation rate 
To estimate mutation rate for each gene, we estimated their intron divergence 
between the human and chimpanzee genomes as follows.  Alignments using 
the NCBI build 36 version of the human genome and PanTro2 version of the 
chimp genome were downloaded from the UCSC website 
(http://genome.ucsc.edu/). Alignments were parsed into individual genic 
sequences and realigned with MAFFT version 6 
(http://mafft.cbrc.jp/alignment/software/). Exon sequences were masked 
according to exon annotation of the NCBI build 36 version of the human 
genome from the ensemble database (http://www.ensembl.org/). We did not 
correct for multiple hits; this is not necessary since the average intron 
divergence between human and chimpanzee sequences is 1.05% [23]. We 
calculated the rates of intron divergence for CpG and nonCpG sites 
separately since the former have much higher rates of mutation. We used 
these intron divergences to infer the rate of non-synonymous mutation in 
human exons, by calculating the number of CpG and non-CpG sites in each 
exon which when mutated would give a non-synonymous change; in this 
calculation we assumed that all mutations at CpGs are transitions, which is a 
good aproximation [25], and that 60% of mutations at other sites were 
transitions. If a gene had multiple transcripts we made these calculations for 
each transcript and averaged the result. 
 
Disease genes 
Genes were designated as being associated with Mendelian disease based 
upon the compilation made by [26]. Genes associated with genome-wide 
association studies (GWAS) were obtained from GWAS catalog 
(http://www.genome.gov/gwastudies/); a gene in which the strongest GWAS 
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signal was found within the boundaries of a gene were designated as being a 
GWAS gene.  
 
Genomic features 
To investigate what factors might influence patterns of genic mutations 
estimated by intron divergence we considered a number of variables.  Intron 
GC content, nucleosome occupancy, replication timing and male and female 
recombination rates were downloaded from the UCSC website 
(http://genome.ucsc.edu/). We used A365 values to study the influence of 
nucleosome occupancy on the distribution of genic mutations rate across the 
genome. Recombination rates per MB were from Kong et al [27]. Replication 
time data, from HELA cells, were from Chen et al. [15]. Germ-line expression 
data were from a study by McVicker and Green [28]. 
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Factor Intron 
Divergence 
Predicted 
non-
synonymous 
mutation 
rate 
Intron 
SNP 
density 
Realized 
effective 
population 
size 
GC content 0.525*** 0.512*** 0.192*** -0.212*** 
Nucleosome 
occupancy 
-0.396*** -0.422*** -0.142*** -0.035 
Female 
recombination 
rate 
-0.020* -0.004 0.058*** 0.042*** 
Male 
recombination 
rate 
0.202*** 0.176*** 0.129*** -0.048*** 
Germ-line 
expression 
-0.062*** -0.090*** -0.020* 0.032*** 
Replication 
time 
0.132*** 0.132*** 0.071*** 0.038*** 
Distance to 
telomere 
-0.158*** -0.154*** -0.117*** 0.060*** 
Distance to 
centromere 
-0.018* -0.008 0.020* 0.014 
 
Table 1. Standardised regression coefficients from multiple regressions. * 
p<0.05, ** p<0.01 and *** p<0.001 
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Figure 1. Mean CDS length. Error bars represent the 95% confidence 
intervals. 
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Figure 2. Mutation rates as inferred from intron divergence between human 
and chimpanzee. A) Intron divergence between human and chimpanzee; B) 
the predicted non-synonymous mutation rate. Error bars represent the 95% 
confidence intervals. 
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Figure 3. The diversity in disease and non-disease genes measured as the A) 
average intron SNP density, B) the average intron SNP density divided by 
intron divergence, C) and the mean minor allele frequency (MAF). Error bars 
represent the 95% confidence intervals. 
 
GWASMendelianNon-disease
M
ea
n 
S
N
P
 d
en
si
ty
0.012
0.010
0.008
0.006
0.004
0.002
0.000
M
ea
n 
M
A
F
0.015
0.010
0.005
0.000
M
ea
n 
R
ea
lti
ve
 E
ffe
ct
iv
e 
po
pu
la
tio
n 
si
ze 1.200
1.000
0.800
0.600
0.400
0.200
0.000
GWASMendelianNon-disease
GWASMendelianNon-disease
A)
B)
C)
 17 
 
